Your children deserve treatment for myopia

Myopia Management

Myopia progression can be controlled, not only corrected; so they can go full steam ahead.

What is myopia?

Myopia, also known as near-sightedness, is a common eye condition in children, whereby distant objects appear blurry and out of focus.¹ This can make it harder for your child to concentrate at school and/or enjoy everyday activities. If left unmanaged, myopia may continue to worsen throughout childhood and increase the risk of serious eye conditions later in life.²

Experience myopia

Shaping the future of vision care

Myopia: biggest eye health threat, set to affect 50% by 2050.

At HOYA, we are dedicated to improving your child's vision health and raising awareness about myopia. We urge governments and health organizations to prioritize myopia for early detection and education. #ActNow

Did you know myopia progression can be controlled, not only corrected?

Most spectacle lenses simply help your child see clearly. While they correct vision, they don't help manage how myopia progresses over time - that's why HOYA created MiYOSMART.

HOYA's myopia management solution

Explore MiYOMSMART products

MiYOSMART iQ

HOYA's most advanced myopia control spectacle lens with a smarter design. Stop myopia progression*, on average, during the first 12 months of wear³,⁴ 

Discover more about MiYOSMART iQ

MiYOSMART

MiYOSMART spectacle lenses use the revolutionary D.I.M.S. Technology to correct the myopic refractive error and provide clear vision.

Discover more about MiYOSMART

Chosen by parents around the world

Over 4 million parents across the world have already chosen MiYOSMART.⁸ MiYOSMART iQ raises the bar even further.

Disclaimer

MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.

MiYOSMART spectacle lenses may not be able to address individuals’ conditions due to natural deficiencies, illness, pre-existing medical conditions and/or advanced age of consumers. The information contained herein is for general information and is not intended to constitute medical advice. Please consult your Eye Care Professional for more information prior to the use of MiYOSMART spectacle lenses.

*Clinically relevant myopia progression defined as Spherical Equivalent Refraction change equal to or superior to -0.50D over 12 months of wear. Outcomes for myopic children aged 4 to 12 years. They may vary per age group and other parameters at the start of MiYOSMART iQ treatment.

  1. (1)

    Turbert D. Nearsightedness: What Is Myopia? American Academy of Ophthalmology. 2022.  Available from: https://www.aao.org/eye-health/diseases/myopia-nearsightedness (Last accessed: June 2025).

  2. (2)

    Haarman AEG, Enthoven CA, Tideman JWL, et al. The Complications of Myopia: A Review and Meta-Analysis. Invest Ophthalmol Vis Sci. 2020;61(4):49. DOI: 10.1167/iovs.61.4.49.

  3. (3)

    Tse D.Y., Hon Y., Chun R. K., Leung T. W., Leung D.K. Y., To C. H., Lam C SY. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Spectacle lens with Triple Enhanced Design: 12-month randomized controlled trial. Abstract 2523, ARVO 2026 Annual Meeting, Denver, USA. https://eppro02.ativ.me/web/index.php page=IntHtml&project=ARVO26&id=4486941 (accessed date 03.04.2026)

  4. (4)

    HOYA data on file. HOYA MiYOSMART iQ spectacle lens clinical outcomes. 04/2026.

  5. (5)

    HOYA data on file. Transmission, traffic light recognition, and UV blocking test for MiYOSMART clear and polarized lenses. 02/2023. Tests were conducted at room temperature (23°C).

  6. (6)

     HOYA data on file. Transmission, traffic light recognition, and UV blocking test for MiYOSMART clear and photochromic lenses. 02/2023. Tests were conducted at room temperature (23°C).

  7. (7)

    MiYOSMART polarized spectacle lenses and inactive MiYOSMART self-tinting spectacle lenses block 100% of harmful UV light, as per the ISO 8980-3:2022 standard.

  8. (8)

    HOYA data on file. MiYOSMART spectacle lens commercial data. 04/2026.